Daxx, a Novel Fas-Binding Protein That Activates JNK and Apoptosis
Abstract
The Fas cell surface receptor induces apoptosis upon receptor oligomerization. We have identified a novel signaling protein, termed Daxx, that binds specifically to the Fas death domain. Overexpression of Daxx enhances Fas-mediated apoptosis and activates the Jun N-terminal kinase (JNK) pathway. A C-terminal portion of Daxx interacts with the Fas death domain, while a different region activates both JNK and apoptosis. The Fas-binding domain of Daxx is a dominant-negative inhibitor of both Fas-induced apoptosis and JNK activation, while the FADD death domain partially inhibits death but not JNK activation. The Daxx apoptotic pathway is sensitive to both Bcl-2 and dominant-negative JNK pathway components and acts cooperatively with the FADD pathway. Thus, Daxx and FADD define two distinct apoptotic pathways downstream of Fas.
Additional Information
© 1997 Cell Press. Under an Elsevier user license. Received 8 January 1997, Revised 8 May 1997. Correspondence regarding this paper should be addressed to D. B. We are indebted to Dr. Genhong Cheng for his help in the initial phase of this project. We thank Drs. R. Brent, Y. W. Choi, C. J. Der, D. V. Goeddel, A. Hoffmann, M. Karin, R. N. Kolesnick, P. H. Krammer, R. J. Lutz, S. Nagata, R. Treisman, D. Wallach, and J. Yuan their generous gifts of reagents, and S. W. Fesik for examining the Daxx sequence. We thank P. Svec and Y. Li for excellent technical assistance, and Drs. A. J. Koleske, B. Chen, Z. Songyang, Y. Yamanashi, I. Stancovsky and other members of Baltimore lab for valuable advice. X. Y. and R. K.-F. are fellows of the Leukemia Society of America and Irvington Research Institute, respectively. H. Y. C. is supported by the Medical Scientist Training Program at Harvard Medical School. D. B. is an American Cancer Society Research Professor. This work was supported by the NIH grant CA51462.Attached Files
Accepted Version - nihms-242914.pdf
Files
Name | Size | Download all |
---|---|---|
md5:bd029a01f6d8999c7b096a9b3144744b
|
445.7 kB | Preview Download |
Additional details
- PMCID
- PMC2989411
- Eprint ID
- 102729
- DOI
- 10.1016/s0092-8674(00)80294-9
- Resolver ID
- CaltechAUTHORS:20200422-150958917
- Leukemia Society of America
- Irvington Institute for Medical Research
- Harvard Medical School
- American Cancer Society
- NIH
- CA51462
- Created
-
2020-04-23Created from EPrint's datestamp field
- Updated
-
2021-11-16Created from EPrint's last_modified field